WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a ...

Based on the results, iTeos and GSK are stopping all ongoing trials of belrestotug, including an ongoing Phase 3 study in lung cancer. iTeos is “taking immediate steps to preserve capital” as ...

“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we’re excited to welcome Dr. Feltquate as Chief Medical Officer,” said Michel ...

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

--iTeos Therapeutics and GlaxoSmithKline plc today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a ...

WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for ...

Turning to iTeos Therapeutics' balance sheet, the company had cash and cash equivalents of $216.2M, short-term investments of $383.0M, and long-term investments of $78.3M as of June 30, 2023.

Shares of iTeos Therapeutics Inc. soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline to develop and commercialize an experimental cancer therapy.

--iTeos Therapeutics, Inc. today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire iTeos for $10.047 in cash per share of iTeos ...